PDF(Pubmed)
Abstract：
UNASSIGNED: Secondary gliosarcomas (SGS) are rare malignancies that are diagnosed subsequent to pre-existing glioma. Clinical features and optimal treatment strategies for SGS have not been conclusively established. This study aimed to assess the clinicopathological features and outcomes of SGS.
UNASSIGNED: We assessed the clinicopathological features and outcomes of SGS via retrospective analysis of data for SGS patients at Tangdu Hospital. Data from SGS patients in prior publications were also analyzed in accordance with PRISMA guidelines.
UNASSIGNED: Eighteen SGS patients who had been treated at Tangdu Hospital between 2013 and 2020 were enrolled in this study. Additional 89 eligible SGS patients were identified from 39 studies. The median age for the patients was 53 years old, and the most common location was the temporal lobe. The most common initial diagnosis was glioblastoma (GBM) (72.0%). Radiology revealed enhanced masses in 94.8% (73/77) of patients. Ten patients (10/107, 9.35%) had extracranial metastases at or after SGS diagnosis. Patients with initial diagnosis of non-GBM and who were younger than 60 years of age were significantly associated with a long duration of disease progression to SGS. After SGS diagnosis, patients with initial non-GBM diagnosis, gross total resection and chemoradiotherapy exhibited prolonged survival outcomes. Patients who had been initially diagnosed with GBM and received both chemoradiotherapy and active therapy after disease progression to SGS, had a significantly longer overall survival than patients who did not.
UNASSIGNED: Initial diagnosis of GBM was a poor prognostic factor for SGS. Patients who underwent gross total resection and chemoradiation had better overall survival outcomes than those who did not. However, during treatment, clinicians should be cognizant of possible extracranial metastases.
UNASSIGNED: We assessed the clinicopathological features and outcomes of SGS via retrospective analysis of data for SGS patients at Tangdu Hospital. Data from SGS patients in prior publications were also analyzed in accordance with PRISMA guidelines.
UNASSIGNED: Eighteen SGS patients who had been treated at Tangdu Hospital between 2013 and 2020 were enrolled in this study. Additional 89 eligible SGS patients were identified from 39 studies. The median age for the patients was 53 years old, and the most common location was the temporal lobe. The most common initial diagnosis was glioblastoma (GBM) (72.0%). Radiology revealed enhanced masses in 94.8% (73/77) of patients. Ten patients (10/107, 9.35%) had extracranial metastases at or after SGS diagnosis. Patients with initial diagnosis of non-GBM and who were younger than 60 years of age were significantly associated with a long duration of disease progression to SGS. After SGS diagnosis, patients with initial non-GBM diagnosis, gross total resection and chemoradiotherapy exhibited prolonged survival outcomes. Patients who had been initially diagnosed with GBM and received both chemoradiotherapy and active therapy after disease progression to SGS, had a significantly longer overall survival than patients who did not.
UNASSIGNED: Initial diagnosis of GBM was a poor prognostic factor for SGS. Patients who underwent gross total resection and chemoradiation had better overall survival outcomes than those who did not. However, during treatment, clinicians should be cognizant of possible extracranial metastases.
摘要：
未经证实：继发性神经胶质肉瘤（SGS）是在先前存在的神经胶质瘤后诊断的罕见恶性肿瘤。SGS的临床特征和最佳治疗策略尚未最终确定。本研究旨在评估SGS的临床病理特征和结果。
UNASSIGNED：我们通过对唐都医院SGS患者数据的回顾性分析，评估了SGS的临床病理特征和结果。还根据PRISMA指南分析了先前出版物中来自SGS患者的数据。
UNASSIGNED：本研究纳入了2013年至2020年在唐都医院接受治疗的18名SGS患者。从39项研究中确定了另外89名合格的SGS患者。患者的中位年龄为53岁，最常见的位置是颞叶。最常见的初始诊断是胶质母细胞瘤（GBM）（72.0％）。放射学显示94.8％（73/77）的患者肿块增大。10例患者（10/107，9.35％）在SGS诊断时或之后发生颅外转移。初始诊断为非GBM且年龄小于60岁的患者与疾病进展至SGS的持续时间显着相关。SGS诊断后，初次诊断为非GBM的患者，总体全切除和放化疗的生存结局延长.最初被诊断为GBM并在疾病进展到SGS后接受放化疗和积极治疗的患者，患者的总生存期明显长于未治疗的患者.
未经证实：初次诊断为GBM是SGS的不良预后因素。接受全切和放化疗的患者比没有接受全切和放化疗的患者有更好的总体生存结果。然而,治疗期间,临床医生应认识到可能的颅外转移。
UNASSIGNED：我们通过对唐都医院SGS患者数据的回顾性分析，评估了SGS的临床病理特征和结果。
UNASSIGNED：本研究纳入了2013年至2020年在唐都医院接受治疗的18名SGS患者。
未经证实：初次诊断为GBM是SGS的不良预后因素。
